Sector: health
Conviction from: NASDAQ
52-week range: 15.8630.96
Acadia Pharmaceuticals is a biopharmaceutical company focused on central nervous system disorders and rare diseases, marketing Nuplazid for Parkinson's psychosis and Daybue for Rett syndrome.
3 tracked filer(s) hold this · 1 opened, 0 added, 2 trimmed in 30-SEP-2026
Aggregate 13FScore 64 — mean of 3 scored holder(s) · buyers (new/add) avg 61. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-02-26 | SCHEDULE 13D/A | BAKER BROS. ADVISORS LP | 25.4% | High | filing |
1 disclosed trade(s) by 1 filer(s).